Partner with Acurex
Acurex is advancing two lead programs supported by clear mechanistic rationale, favorable safety profile, ease of patient compliance and paths to the clinic validated by others.
We are actively exploring licensing, co-development, pre-option, and partner-funded research around our lead assets and discovery platform.
Our Assets
Acurex presents partnering opportunities for novel, IP-protected assets supported by strong preclinical data.
Our programs address the convergence of aging, genetics, and environmental toxins by modulating key drivers of disease, specifically ferroptosis, neuroinflammation, and mitochondrial dysfunction.
By rescuing alpha-synuclein pathology and preventing neuronal death, we are positioning our assets to capture significant untapped markets in neurodegeneration.
Contact us to learn more about our assets:
Business Development & Strategic Partnerships: